(Q40687098)
Statements
Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study (English)
S L Graziano
A Tatum
J E Herndon
J Box
V Memoli
1 August 2001